Literature DB >> 32034084

Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10.

Fabiana Santos Pacheco1, Rhana Berto da Silva Prata1, Sheila Santos Brandão1, Helen Ferreira1, Thaís Fernanda Rodrigues2, Jéssica Brandão Dos Santos1, Camila Oliveira da Silva2, Isabella Forasteiro Tavares1, Mayara Abud Mendes1, Ana Carolina Duarte Pereira Rodrigues1, Alice de Miranda Machado1, José Augusto da Costa Nery1, Thaís Porto Amadeu3, Milton Ozório Moraes1, Euzenir Nunes Sarno1, Veronica Schmitz4.   

Abstract

Erythema nodosum leprosum (ENL) is an inflammatory complication in leprosy. Yet, the involvement of ENL neutrophils in the inflammatory response against Mycobacterium leprae remains poorly explored. Our primary aim was to investigate the utility of the surface expression of neutrophil IL-10R1 as an ENL biomarker and, secondarily, to evaluate whether leprosy or healthy M. leprae-stimulated neutrophils produce cytokines and are able to respond to IL-10. We, in this study, describe a subpopulation of circulating neutrophils of ENL patients that exclusively expressed IL-10R1, providing evidence that IL-10R1+ neutrophils are present in ENL lesions. It was also found that ENL neutrophils, but not those of nonreactional leprosy controls, were able to secret detectable levels of TNF ex vivo and the addition of IL-10 blocked TNF release. It was likewise observed that M. leprae-stimulated, healthy neutrophils expressed IL-10R1 in vitro, and ENL-linked cytokines were released by M. leprae-cultured neutrophils in vitro. Moreover, consistent with the presence of a fully functional IL-10R, the addition of IL-10 prevented the release of M. leprae-induced cytokines. Most importantly, dead M. leprae revealed its superior capacity to induce CCL4 and IL-8 in primary neutrophils over live Mycobacterium, suggesting that M. leprae may hamper the inflammatory machinery as an immune escape mechanism.
Copyright © 2020 The Authors.

Entities:  

Year:  2020        PMID: 32034084     DOI: 10.4049/immunohorizons.1900088

Source DB:  PubMed          Journal:  Immunohorizons        ISSN: 2573-7732


  6 in total

1.  Case Report: Rapid Response to Low-Dose Thalidomide in a Case of Severe Steroid Recalcitrant Erythema Nodosum Leprosum.

Authors:  Bathula Savitha; Kabir Sardana; Ritu Kumari; Ananta Khurana; Surabhi Sinha; Soumya Sachdeva
Journal:  Am J Trop Med Hyg       Date:  2021-10-18       Impact factor: 3.707

2.  Illumination of Molecular Pathways in Multiple Sclerosis Lesions and the Immune Mechanism of Matrine Treatment in EAE, a Mouse Model of MS.

Authors:  Mengmeng Dou; Xueliang Zhou; Lifeng Li; Mingliang Zhang; Wenbin Wang; Mengru Wang; Yilei Jing; Rui Ma; Jie Zhao; Lin Zhu
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

3.  COVID-19, leprosy, and neutrophils.

Authors:  Veronica Schmitz; Jéssica Brandão Dos Santos
Journal:  PLoS Negl Trop Dis       Date:  2021-01-07

4.  Bioinformatics study on different gene expression profiles of fibroblasts and vascular endothelial cells in keloids.

Authors:  Weihan Zheng; Guojian Lin; Zhizhou Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

5.  The Type I Interferon Pathway Is Upregulated in the Cutaneous Lesions and Blood of Multibacillary Leprosy Patients With Erythema Nodosum Leprosum.

Authors:  Thabatta Leal Silveira Andrezo Rosa; Mayara Abud Mendes; Natasha Ribeiro Cardoso Linhares; Thais Fernanda Rodrigues; André Alves Dias; Thyago Leal-Calvo; Mariana Gandini; Helen Ferreira; Fabrício da Mota Ramalho Costa; Anna Maria Sales; Thaís Porto Amadeu; Veronica Schmitz; Roberta Olmo Pinheiro; Luciana Silva Rodrigues; Milton Ozório Moraes; Maria Cristina Vidal Pessolani
Journal:  Front Med (Lausanne)       Date:  2022-06-06

Review 6.  Neutrophil NETworking in ENL: Potential as a Putative Biomarker: Future Insights.

Authors:  Smrity Sahu; Keshav Sharma; Maryada Sharma; Tarun Narang; Sunil Dogra; Ranjana Walker Minz; Seema Chhabra
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.